Looking for some new additions to your portfolio after earnings season? Listed below are two ASX growth shares that have recently been given buy ratings by Goldman Sachs.
Here's why its analysts rate them highly right now:
Breville Group Ltd (ASX: BRG)
The first ASX growth share that is highly rated by Goldman Sachs following earnings season is Breville.
It is the leading appliance manufacturer behind brands such as Breville, Sage, Kambrook, and Baratza.
As many readers will be aware, these appliances are found in countless kitchens across Australia. And thanks to the company's ongoing and highly successful international expansion, you may have noticed them popping up in kitchens across Europe if you were holidaying abroad this winter.
Goldman Sachs is very positive on the company. It highlights that Breville is exposed to some powerful trends and its strong brands are well-placed to benefit from them.
Goldman has a buy rating and $24.70 price target on the company's shares.
ResMed Inc. (ASX: RMD)
Another ASX growth share that Goldman is tipping as a buy is ResMed.
It is a medical device company with a focus on sleep treatment and respiratory products that treat disorders including sleep apnoea and chronic obstructive pulmonary disease (COPD).
These are significant and growing markets to target. For example, the company highlights that upwards of 1 in 5 people are believed to suffer from sleep apnoea, with the vast majority currently undiagnosed. This bodes well for ResMed's future growth, especially given its industry-leading products, high level of research and development, and wide distribution network.
Goldman Sachs currently has a buy rating and $36.80 price target on its shares.
